Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Written Informed Consent has been obtained~* OAB (symptoms of urgency) according to International Children's Continence Society (ICCS) criteria~* Daytime incontinence with at least 4 or more episodes of incontinence confirmed by 7 day participant diary~Main Exclusion Criteria:~* Daily voiding frequency less than 5~* Extraordinary daytime urinary frequency according to the International Children's Continence Society (ICCS) definition~* Uroflow indicative of pathology other than OAB~* Maximum voided volume (morning volume excluded) \> expected bladder capacity for age \[(age +1) x 30\] in ml or a maximum voided volume (morning volume excluded) above 390 ml~* Post Void Residual (PVR) \> 20 ml~* Monosymptomatic enuresis~* Polyuria defined as \> 75 ml/kg/b.w./24 hours~* Dysfunctional voiding~* Congenital anomalies affecting lower urinary tract function~* Current constipation~* Current Urinary Tract Infection (UTI)~* Catheterization within 2 weeks prior to screening

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Children (Type: PLACEBO_COMPARATOR): Children aged 5 to 11 years received matching placebo suspension once a day for 12 weeks.
- Solifenacin Succinate Suspension Children (Type: EXPERIMENTAL): Children aged 5 to 11 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.
- Placebo Adolescents (Type: PLACEBO_COMPARATOR): Adolescents aged 12 to 17 years received matching placebo suspension once a day for 12 weeks.
- Solifenacin Succinate Suspension Adolescents (Type: PLACEBO_COMPARATOR): Adolescents aged 12 to 17 years received solifenacin succinate suspension once a day for 12 weeks. The initial dose started with pediatric equivalent dose (PED) of 5 mg (PED5) based on weight and was titrated up or down to reach the optimal dose. The minimum dose was PED2.5, and the maximum dose was PED10.

Based on this trial design, predict the completion outcome and termination type (if applicable).